Home › Funds › Commodore Capital LP › ELVN

Commodore Capital LP position in ELVN

ENLIVEN THERAPEUTICS INC · Health Care

Commodore Capital LP reported holding 3,275,000 shares of ELVN (ENLIVEN THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$166.2M, representing 9.90% of its reported portfolio and ranking #2 among its reported holdings. Commodore Capital LP has disclosed ELVN holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)3.27M sh
Reported value held$166.21M
Portfolio Weight9.90%
First reportedQ3 2023
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Commodore Capital LP's ELVN position evolved

Commodore Capital LP first disclosed a stake in ELVN in Q3 2023 at 2,901,816 shares (US$39.6M). The position peaked in Q2 2026 at 3,275,000 shares, worth US$166.2M. Across 12 filings, Commodore Capital LP increased the stake 4 time(s), trimmed it 1 time(s) and left it unchanged 6 time(s). The most recent filing (Q2 2026) shows 3,275,000 shares valued at US$166.2M. Notable position changes include a 37% increase in Q1 2024 (shares rose 33% over the following quarter), a 30% trim in Q1 2026 (shares rose 29% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 2.90M $39.64M New
Q4 2023 2.90M $40.16M Hold
Q1 2024 3.97M $69.89M Add
Q2 2024 3.97M $92.85M Hold
Q3 2024 4.10M $104.71M Add
Q4 2024 4.21M $94.61M Add
Q1 2025 4.67M $92.00M Add
Q2 2025 4.69M $94.14M Hold
Q3 2025 4.69M $96.06M Hold
Q4 2025 4.69M $72.27M Hold
Q1 2026 3.27M $128.38M Reduce
Q2 2026 3.27M $166.21M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ELVN and 13F data

ELVN (ENLIVEN THERAPEUTICS INC) is a Health Care company. 67 other funds we track also report a position in ELVN — the largest reported positions include ORBIMED ADVISORS LLC (US$343.9M), Polar Capital Holdings Plc (US$326.4M), Vestal Point Capital, LP (US$203.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ELVN

All ELVN fund holders →

FAQ

How long has Commodore Capital LP held ELVN?

Commodore Capital LP has disclosed ELVN holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Commodore Capital LP's current position in ELVN?

As of Q2 2026, Commodore Capital LP holds 3.27M shares of ELVN (ENLIVEN THERAPEUTICS INC), valued at $166.21M, representing 9.90% of its reported portfolio and ranking #2.

Has Commodore Capital LP been buying or selling ELVN?

In the latest 13F filing (Q2 2026), Commodore Capital LP held unchanged its position in ELVN. The position peaked in Q2 2026 at 3.27M shares.

Which other funds hold ELVN?

Other major institutional holders of ELVN include ORBIMED ADVISORS LLC, Polar Capital Holdings Plc, Vestal Point Capital, LP, among 67 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.